{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:21:00Z","timestamp":1757618460870,"version":"3.44.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06470-3","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T01:02:03Z","timestamp":1751504523000},"page":"3733-3743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of C-reactive protein\/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Akihiko","family":"Izumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"8","key":"6470_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jcyt.2024.03.490","volume":"26","author":"T Tachibana","year":"2024","unstructured":"Tachibana T, Miyazaki T, Matsumura A et al (2024) Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation. Cytotherapy. 26(8):921\u2013929. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.490","journal-title":"Cytotherapy."},{"key":"6470_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al (2017) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. ref. 4th ed. IARC: Lyon"},{"issue":"6","key":"6470_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK et al (2019) Acute Myeloid Leukemia, Version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 17(6):721\u2013749. https:\/\/doi.org\/10.6004\/jnccn.2019.0028","journal-title":"J Natl Compr Canc Netw."},{"issue":"8","key":"6470_CR4","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"6","key":"6470_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","volume":"120","author":"R Raimondi","year":"2012","unstructured":"Raimondi R, Tosetto A, Oneto R et al (2012) Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 120(6):1327\u20131333. https:\/\/doi.org\/10.1182\/blood-2012-03-414573","journal-title":"Blood"},{"issue":"3","key":"6470_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 15(3):367\u2013369","journal-title":"Biol Blood Marrow Transplant."},{"key":"6470_CR7","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15(6):825\u2013828"},{"issue":"3","key":"6470_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6470_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1586\/ehm.10.81","volume":"4","author":"J Kanda","year":"2011","unstructured":"Kanda J, Kawabata H, Chao NJ (2011) Iron overload and allogeneic hematopoietic stem-cell transplantation. Expert Rev Hematol 4(1):71\u201380. https:\/\/doi.org\/10.1586\/ehm.10.81","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"6470_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.bbmt.2008.08.004","volume":"14","author":"AS Artz","year":"2008","unstructured":"Artz AS, Wickrema A, Dinner S et al (2008) Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 14(11):1209\u20131216. https:\/\/doi.org\/10.1016\/j.bbmt.2008.08.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6470_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/bmt.2010.108","volume":"46","author":"J Kanda","year":"2011","unstructured":"Kanda J, Mizumoto C, Ichinohe T et al (2011) Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 46(2):208\u2013216. https:\/\/doi.org\/10.1038\/bmt.2010.108","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6470_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12185-012-1229-0","volume":"97","author":"S Sakamoto","year":"2013","unstructured":"Sakamoto S, Kawabata H, Kanda J et al (2013) Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97(1):109\u2013116. https:\/\/doi.org\/10.1007\/s12185-012-1229-0","journal-title":"Int J Hematol"},{"issue":"5","key":"6470_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/bmt.2012.193","volume":"48","author":"M Sato","year":"2013","unstructured":"Sato M, Nakasone H, Oshima K et al (2013) Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. Bone Marrow Transplant 48(5):698\u2013702. https:\/\/doi.org\/10.1038\/bmt.2012.193","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"6470_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3324\/haematol.2016.145847","volume":"101","author":"AS Artz","year":"2016","unstructured":"Artz AS, Logan B, Zhu X et al (2016) The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica 101(11):1426\u20131433. https:\/\/doi.org\/10.3324\/haematol.2016.145847","journal-title":"Haematologica"},{"issue":"4","key":"6470_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s12185-016-1941-2","volume":"103","author":"W Yamamoto","year":"2016","unstructured":"Yamamoto W, Fujii E, Matsumoto K et al (2016) Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Int J Hematol 103(4):444\u2013452. https:\/\/doi.org\/10.1007\/s12185-016-1941-2","journal-title":"Int J Hematol"},{"issue":"8","key":"6470_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014474","volume":"98","author":"P Wu","year":"2019","unstructured":"Wu P, Liang W, Chen X et al (2019) Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 98(8):e14474. https:\/\/doi.org\/10.1097\/MD.0000000000014474","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"6470_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.14454","volume":"180","author":"A Patel","year":"2018","unstructured":"Patel A, Szydlo RM, Auner HW et al (2018) C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality. Br J Haematol 180(6):889\u2013892. https:\/\/doi.org\/10.1111\/bjh.14454","journal-title":"Br J Haematol"},{"key":"6470_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106574","volume":"105","author":"S Li","year":"2021","unstructured":"Li S, Gu J, Nan W et al (2021) Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients. Leuk Res 105:106574. https:\/\/doi.org\/10.1016\/j.leukres.2021.106574","journal-title":"Leuk Res"},{"issue":"3","key":"6470_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jinf.2013.05.005","volume":"67","author":"R Ram","year":"2013","unstructured":"Ram R, Yeshurun M, Farbman L, Herscovici C, Shpilberg O, Paul M (2013) Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation. J Infect 67(3):194\u2013198. https:\/\/doi.org\/10.1016\/j.jinf.2013.05.005","journal-title":"J Infect"},{"issue":"5","key":"6470_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bbmt.2019.01.006","volume":"25","author":"E Miyashita","year":"2019","unstructured":"Miyashita E, Konuma T, Kataoka J, Oiwa-Monna M, Mizusawa M, Isobe M et al (2019) The prognostic impact of pretransplantation inflammatory and nutritional status in adult patients after myeloablative single cord blood transplantation. Biol Blood Marrow Transplant 25(5):981\u2013988","journal-title":"Biol Blood Marrow Transplant"},{"key":"6470_CR21","doi-asserted-by":"publisher","unstructured":"Wang K, Jian X, Xu Z, Wang H (2023) Pre-transplant CRP-albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. Front Immunol. 14:1128982. Published 2023 Feb 15. https:\/\/doi.org\/10.3389\/fimmu.2023.1128982","DOI":"10.3389\/fimmu.2023.1128982"},{"issue":"4","key":"6470_CR22","doi-asserted-by":"publisher","first-page":"400.e1","DOI":"10.1016\/j.jtct.2024.01.068","volume":"30","author":"T Miyazaki","year":"2024","unstructured":"Miyazaki T, Tachibana T, Suzuki T et al (2024) Pretransplantation inflammatory and nutritional status in elderly allogeneic hematopoietic stem cell transplantation: prognostic value of C-reactive protein-to-albumin ratio. Transplant Cell Ther 30(4):400.e1-400.e9. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.068","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"6470_CR23","doi-asserted-by":"publisher","first-page":"187.e1","DOI":"10.1016\/j.jtct.2023.11.016","volume":"30","author":"A Pedraza","year":"2024","unstructured":"Pedraza A, Salas MQ, Rodr\u00edguez-Lobato LG et al (2024) Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation. Transplant Cell Ther 30(2):187.e1-187.e12. https:\/\/doi.org\/10.1016\/j.jtct.2023.11.016","journal-title":"Transplant Cell Ther"},{"key":"6470_CR24","doi-asserted-by":"publisher","unstructured":"Jiang S, Penack O, Terzer T, et al. (2021) Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. Haematologica. 106(2):446\u2013453. Published 2021 Feb 1. https:\/\/doi.org\/10.3324\/haematol.2019.238790","DOI":"10.3324\/haematol.2019.238790"},{"issue":"7","key":"6470_CR25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.bbmt.2010.02.008","volume":"16","author":"M Palomo","year":"2010","unstructured":"Palomo M, Diaz-Ricart M, Carbo C et al (2010) Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 16(7):985\u2013993. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6470_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12033-023-01010-8","volume":"66","author":"N Kazemi","year":"2024","unstructured":"Kazemi N, Bordbar A, Bavarsad SS, Ghasemi P, Bakhshi M, Rezaeeyan H (2024) Molecular insights into the relationship between platelet activation and endothelial dysfunction: molecular approaches and clinical practice. Mol Biotechnol 66(5):932\u2013947. https:\/\/doi.org\/10.1007\/s12033-023-01010-8","journal-title":"Mol Biotechnol"},{"issue":"5","key":"6470_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","volume":"81","author":"DS Genest","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C, John R, Reich HN (2023) Renal thrombotic microangiopathy: A review. Am J Kidney Dis 81(5):591\u2013605. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.014","journal-title":"Am J Kidney Dis"},{"key":"6470_CR28","doi-asserted-by":"publisher","unstructured":"Xu ZL, Ji J, Wang SB, et al. (2025) Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group. Haematologica. 110(3):629\u2013639. Published 2025 Mar 1. https:\/\/doi.org\/10.3324\/haematol.2024.286040","DOI":"10.3324\/haematol.2024.286040"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06470-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:38:00Z","timestamp":1757205480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6470"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06470-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) of the participating institutions (Kanagawa Cancer Center 2022-eki-22, Yokohama City University Medical Center F220700057, Yokohama City University Hospital F220700056) and complied with the Declaration of Helsinki. The requirement for informed consent was waived by the IRB, considering that no intervention was involved due to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"TT reports honoraria from Pfizer, Otsuka, MSD, Chugai, AbbVie, Astellas, Novartis, Nippon Shinyaku, Asahi Kasei Pharma, Daiichi Sankyo, and Amgen, outside the submitted work. SF reports honoraria from Novartis, Pfizer, Otuska Pharmaceutical, Nipppon Shinyaku, Chugai Pharmaceutical, Takeda, Janssen, AstraZeneca, AbbVie Inc, Meiji Seika Pharma, AsahiKasei, CSL Behring K.K, Asahi Kasei Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Kissei, PharmaEssentia Japan, Genmab, Argenx Japan, and Amgen, and research funding from Amgen, Otuska Pharmaceutical, Kyowa Hakko Kirin, Chugai Pharmaceutical, and AsahiKasei, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}